Back to top
more

Cencora, Inc. (COR)

(Delayed Data from NYSE)

$225.38 USD

225.38
1,614,264

+3.18 (1.43%)

Updated Jul 16, 2024 04:00 PM ET

After-Market: $225.43 +0.05 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (102 out of 250)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

ResMed (RMD) to Treat Sleep Apnea With New AirCurve 11 (Revised)

by Zacks Equity Research

ResMed's (RMD) new AirCurve11 series incorporates MyAir and AirView digital health apps to provide maximum comfort and support during therapy.

Bio-Rad (BIO) Q4 Earnings Beat, Revenues Miss, Margins Down

by Zacks Equity Research

Bio-Rad (BIO) continues to experience weak demand for Life Science products in China.

Labcorp (LH) Q4 Earnings and Revenues Beat, Margins Fall

by Zacks Equity Research

Strength in Diagnostics Laboratories and Biopharma Laboratory Services businesses contributes to Labcorp's (LH) Q4 performance.

Here's Why You Should Retain IDEXX (IDXX) Stock for Now

by Zacks Equity Research

Investors are optimistic about IDEXX (IDXX) growth in CAG business and strong global performance

Avantor (AVTR) Q4 Earnings & Revenues Top Estimates, Margins Down

by Zacks Equity Research

Despite Avantor's (AVTR) continued stability in end markets, it reports an overall soft fourth-quarter performance.

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here's Why You Should Retain CVS Health (CVS) Stock for Now

by Zacks Equity Research

Investors are optimistic about CVS Health (CVS) on its strong segmental performance and impressive restructuring plan.

Bruker (BRKR) Q4 Earnings Surpass Estimates, Margins Down

by Zacks Equity Research

Strength in BioSpin and CALID groups contributes to Bruker's (BRKR) Q4 revenues.

Charles River (CRL) Q4 Earnings Surpass, Margins Contract

by Zacks Equity Research

Charles River (CRL) delivers better-than-expected revenues and earnings in the fourth quarter of 2023.

DaVita (DVA) Q4 Earnings & Revenues Top Estimates, Margins Up

by Zacks Equity Research

DaVita's (DVA) robust segmental revenues drive its fourth-quarter performance.

Ecolab (ECL) Q4 Earnings Surpass Estimates, Margins Rise

by Zacks Equity Research

Ecolab's (ECL) robust performance across the majority of its segments drives its fourth-quarter sales despite business challenges.

Omnicell (OMCL) Q4 Earnings Top Estimates, Gross Margin Down

by Zacks Equity Research

Omnicell's (OMCL) fourth-quarter 2023 performance favorably reflects a heightened focus on managing costs.

Zacks Industry Outlook Highlights Elevance Health, Cencora and HealthEquity

by Zacks Equity Research

Elevance Health, Cencora and HealthEquity have been highlighted in this Industry Outlook article.

Urmimala Biswas headshot

3 Medical Services Stocks to Buy Amid Industry Headwinds

by Urmimala Biswas

The Zacks Medical - Services industry is growing on digital healthcare adoption. ELV, COR and HQY are set to gain the most. However, staffing shortages continue to disrupt the growth trend.

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Cencora, Inc. (COR) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Cencora (COR) is a Top-Ranked Growth Stock: Should You Buy?

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Is Cencora, Inc. (COR) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Cencora (COR) and Cigna (CI) have performed compared to their sector so far this year.

Cencora (COR) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

The headline numbers for Cencora (COR) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Cencora (COR) Beats on Q1 Earnings & Revenues, Ups 2024 Outlook

by Zacks Equity Research

Cencora's (COR) first-quarter fiscal 2024 results benefit from overall market growth, including rising demand for GLP-1 drugs and COVID-19 vaccines. Inflationary pressure remains.

Cencora (COR) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Cencora (COR) delivered earnings and revenue surprises of 14.69% and 5%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Why Cencora (COR) Could Beat Earnings Estimates Again

by Zacks Equity Research

Cencora (COR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Indrajit Bandyopadhyay headshot

Medical Product Stocks' Q4 Earnings Due on Jan 30: SYK & More

by Indrajit Bandyopadhyay

Fourth-quarter results of Medical Product companies are likely to reflect a year-over-year improvement in revenues. Let's see how SYK, COR and ARAY fare this time around.

Cencora (COR) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Cencora's (COR) first-quarter fiscal 2024 results are likely to reflect solid performance at the U.S. Healthcare Solutions segment.

Unlocking Q1 Potential of Cencora (COR): Exploring Wall Street Estimates for Key Metrics

by Zacks Equity Research

Besides Wall Street's top -and-bottom-line estimates for Cencora (COR), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.